American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Caristo Diagnostics United Kingdom England Georgia United States of America California

Americans visit hospital emergency departments complaining of chest pain every year. Many will undergo a coronary CT angiography (CCTA) scan to diagnose coronary artery disease caused by plaques that narrow or block the arteries supplying blood to the heart. Three quarters of patients undergoing CCTAs will display no clear sign of significant narrowing. Yet there are twice as many deaths or cardiac events among these "low risk" patients than among those identified as high-risk. A primary cause of these events is coronary inflammation, a crucial risk factor previously unseen in routine CCTAs.

The CaRi-Heart FAI-Score can be derived from routine CCTA scans to reveal otherwise invisible coronary inflammation and calculate a patient's individualized risk of suffering a fatal cardiac event. Given the significant number of patients who receive a negative CCTA result yet remain at high risk of acute cardiovascular events, the ability to manage coronary inflammation related residual risk remains a major unmet need. The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

About Abcentra

Abcentra is a clinical stage biopharmaceutical company with a mission to improve treatment options for patients with coronary artery disease (CAD). Abcentra's core technology allows for targeting of oxidized low-density lipoprotein (OxLDL), a novel and highly specific approach to quelling coronary inflammation, which has the potential to maximize efficacy and safety compared to other anti-inflammatory therapies for CAD.

The Company's clinical-stage product, Orticumab, is a first-in-class monoclonal antibody against oxidized LDL (OxLDL), the critical driver of atherosclerotic disease and heart attack. Abcentra is developing Orticumab for secondary prevention of cardiac events after an acute coronary syndrome (ACS), with further plans to expand use of orticumab into primary prevention in CAD patients with coronary inflammation.

Abcentra is based in Los Angeles, California.

 

About Caristo Diagnostics
Caristo Diagnostics is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world's #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo was highlighted by Nature in 2020 as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X. 

Abcentra contact:
Vicky Lu, Clinical Development Associate
[e-mail] 

Caristo Diagnostics contact:
Frank Cheng, CEO
[e-mail]

Logo - https://mma.prnewswire.com/media/2380898/4635069/Abcentra_Logo.jpg
Logo - https://mma.prnewswire.com/media/2054669/4634936/Caristo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/american-college-of-cardiology-presentation-highlights-promising-results-showing-potential-to-reduce-coronary-inflammation-with-abcentras-orticumab-302110107.html